A 72-year-old client with non-valvular atrial fibrillation i… | MyMerci
Medical EmergenciesPA
Question
A 72-year-old client with non-valvular atrial fibrillation is starting apixaban 5 mg orally twice daily for stroke prevention. Which statement by the client demonstrates correct understanding?
1I will take my apixaban once daily in the morning, since it provides 24-hour protection, and I will not need to inform any healthcare provider before procedures like dental cleanings or skin biopsies because routine monitoring is not required and it has fewer restrictions than warfarin.
2I will take this medication twice a day approximately 12 hours apart, with or without food, and contact the provider before any new prescription, OTC, or herbal product because routine INR is not used but the medication still has many drug interactions.✓ Correct answer
3Since routine blood testing is unnecessary with apixaban, it is safe for me to take ibuprofen for my arthritis and to use herbal products like St. John's wort or ginkgo without checking with my provider, because these substances interact with warfarin and pose no risk with this medication.
4I plan to monitor my pulse and stop apixaban when my rhythm feels regular, because the danger of clots is temporary, and if I miss a few doses, I can restart with a double dose to quickly restore protection without needing to inform my provider.
Explanation
Apixaban — patient teaching Apixaban is a direct factor Xa inhibitor used for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of VTE.
Key teaching: • 5 mg PO twice daily approximately 12 hours apart; reduce to 2.5 mg BID if any 2 of: age ≥80, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. • Take with or without food; do NOT crush or split unless using the pre-approved crushed-administration option (apixaban CAN be crushed and dispersed in water/apple juice for NG tube — different from dabigatran). • No routine coagulation monitoring — apixaban does NOT prolong INR predictably, so INR is not used. Anti-Xa specific to apixaban can confirm presence in select cases. • Drug interactions: avoid concurrent strong CYP3A4 / P-gp inhibitors (ketoconazole, ritonavir) — increase bleeding; strong inducers (rifampin, phenytoin, carbamazepine, St. Johns wort) reduce effect. • Bleeding precautions: soft toothbrush, electric razor, fall prevention, avoid IM injections, avoid NSAIDs/aspirin without provider, report any bruising/dark stool/pink urine/persistent headache/fall. • Do NOT self-discontinue: even when rhythm feels normal, afib stroke risk persists; abrupt cessation increases stroke risk significantly. • Surgery: hold 24–48 hours pre-op (low risk) or 48 hours+ (high risk) per provider; resume per surgeon. • Reversal: andexanet alfa for major bleeding; PCC alternative if andexanet unavailable.
In-depth explanation
Clinical reasoning summary Apixaban — patient teaching Apixaban is a direct factor Xa inhibitor used for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of VTE.
Key teaching: • 5 mg PO twice daily approximately 12 hours apart; reduce to 2.5 mg BID if any 2 of: age ≥80, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. • Take with or without food; do NOT crush or split unless using the pre-approved crushed-administration option (apixaban CAN be crushed and dispersed in water/apple juice for NG tube — different from dabigatran). • No routine coagulation monitoring — apixaban does NOT prolong INR predictably, so INR is not used. Anti-Xa specific to apixaban can confirm presence in select cases. • Drug interactions: avoid concurrent strong CYP3A4 / P-gp inhibitors (ketoconazole, ritonavir) — increase bleeding; strong inducers (rifampin, phenytoin, carbamazepine, St. Johns wort) reduce effect. • Bleeding precautions: soft toothbrush, electric razor, fall prevention, avoid IM injections, avoid NSAIDs/aspirin without provider, report any bruising/dark stool/pink urine/persistent headache/fall. • Do NOT self-discontinue: even when rhythm feels normal, afib stroke risk persists; abrupt cessation increases stroke risk significantly. • Surgery: hold 24–48 hours pre-op (low risk) or 48 hours+ (high risk) per provider; resume per surgeon. • Reversal: andexanet alfa for major bleeding; PCC alternative if andexanet unavailable.